LUPUS ERYTHEMATOSUS, SYSTEMIC

This study is tracking 125 adults with lupus who are starting a new drug called anifrolumab. The goal is to see how well the drug controls disease activity and helps patients achieve remission over two years. Researchers are collecting data from regular doctor visits and patient …

This study tests a one-time cell therapy called rapcabtagene autoleucel for people with active lupus that hasn't improved with standard treatments. About 179 adults will receive the therapy after a short course of chemotherapy to prepare their bodies. The goal is to see if the tr…

This early-stage study tests a one-time treatment made from donor immune cells that are gene-edited to target and destroy faulty immune cells causing disease. It is for 80 adults with severe lupus, scleroderma, or myositis that have not responded to standard therapies. The main g…

This study looks at how well the drug anifrolumab works in real life for people with lupus. The goal is to see if it helps patients achieve low disease activity while taking a low dose of steroids (5 mg or less per day). About 218 adults in Italy will be followed for a year. This…

This study tracks 100 adults with lupus who are taking anifrolumab as part of their normal treatment in Poland. Researchers will measure changes in disease activity and overall health over time. The goal is to see how well the drug works outside of controlled trials, in real-life…

This study tests whether nipocalimab can reduce lupus disease activity better than a placebo. It involves 600 adults with moderate to severe lupus. The main goal is to see how many people achieve a meaningful reduction in symptoms after 52 weeks of treatment.

This study tests a new treatment called AZD0120 for adults with severe lupus that hasn't improved with standard therapies. AZD0120 uses a patient's own immune cells, modified to target and destroy faulty immune cells that drive lupus. The trial has two phases: first to find a saf…

This study tests if cenerimod, added to standard care, helps adults with lupus-related kidney disease. About 300 participants will take either cenerimod or a placebo daily for 76 weeks. The main goal is to see if the drug improves kidney function and is safe. Regular clinic visit…

This study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and destroy faulty B cells that drive lupus. It is for people with active systemic lupus erythematosus (SLE) or lupus nephritis who have not improved with steroids and…

This study looks at how 45, 90, or 150 minutes of physical activity each week affects arthritis symptoms like pain and mobility. Researchers will track changes in walking distance and other physical functions. The goal is to find the most effective amount of exercise for people w…

This study tests a brief behavioral treatment delivered over Zoom for adults with fibromyalgia, lupus, chronic pelvic pain, or chronic low back pain. The goal is to help participants learn strategies to reduce pain, disability, and related issues like depression or anxiety. About…

This study aims to find blood markers that could predict serious side effects from cancer immunotherapy. Researchers will measure interferon levels in 300 cancer patients starting immunotherapy and compare them to 40 people with autoimmune diseases like lupus. The goal is to deve…

This study looks at how natural cannabis compounds (like CBD and THC) affect immune cells from 100 people with chronic inflammatory diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease. Researchers will take a blood sample and expose the cells to different…